Stock Analiz

Azitra, Inc. AZTR

Biotechnology: Pharmaceutical Preparations · IPO 2023 · data as of November 13, 2026

$0.61Market cap $4M
Open the interactive analysis →

Azitra, Inc. (AZTR) is a healthcare company listed in the US with a market value of about $4M.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -167%.

About Azitra

Azitra is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2023. It was profitable in 0 of the last 4 years in our data. Its share count rose by 13810% over three years (dilution for shareholders).

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B0.8
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-315.8%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-100.0%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-41668.5%
ROIC (5-yr avg.)-167.2%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 4 years

Fiscal year2025202420232022
Revenue$0$7500$686000$284000
Net income-$11M-$9M-$11M-$11M
Free cash flow-$11M-$10M-$7M-$8M
EPS (diluted)$-2.25$-15.70$-54.98$-383.78
Net margin—-119600.0%-1644.9%-3760.7%
ROIC-205.6%-139.3%-156.6%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 2 analysts is $3.50, 475% above the current price; targets range from $3.00 to $4.00; the consensus rating is “Buy”; expected EPS is $-2.05 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Azitra pay a dividend?

Not currently.

Is Azitra a good stock to buy?

We do not give buy or sell advice. Azitra scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.